{"analyses":[{"ciLowerLimit":"0.763","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.506","estimateComment":"Hazard ratio (anetumab ravtansine/vinorelbine) was estimated using Cox proportional hazards models with Wald CIs, stratified by TTP on 1st line treatment.","groupDescription":"OS anetumab ravtansine / vinorelbine","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.655624","pValueComment":"1-sided p-value from log-rank test (stratified by TTP on 1st line treatment). Alpha spending/boundary for interim was 0.00245. Alpha boundary value for final analysis was 0.02421.","paramType":"Hazard Ratio (HR)","paramValue":"1.072","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.3","upperLimit":"12.3","value":"9.5"},{"groupId":"OG001","lowerLimit":"8.6","upperLimit":"13.1","value":"11.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as time from randomization until death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Test drug: 6.5 mg/kg every 3 weeks; Intravenous (IV) infusion over 1 hour","id":"OG000","title":"Anetumab Ravtansine"},{"description":"Active comparator: 30 mg/m\\^2 once weekly","id":"OG001","title":"Vinorelbine"}],"paramType":"MEDIAN","populationDescription":"The secondary efficacy analysis (OS) was performed in the ITT (Intent-to-treat) analysis set.","reportingStatus":"POSTED","timeFrame":"Up to approx. 40 months (data cut-off: 06-Apr-2018) - Time from randomization until death from any cause; one-sided log-rank test stratified by time to progression (TTP) on first line treatment.","title":"Overall Survival (OS), [95% CI]","type":"SECONDARY","unitOfMeasure":"months"}